Traditional pharmaceuticals target an enzyme or a receptor. At Myto Health we are targeting mitochondria. Pharmaceuticals that repair damaged mitochondria and promote growth of new mitochondria are secret to poly-indication drugs.
Mitochondrial dysfunction is linked to several diseases. Pharmaceuticals that restore mitochondrial integrity and function is expected to have therapeutic benefit in neurodegenerative disease, cardiac dysfunction as well as muscular disorders.
As ubiquitin proteasome system (UPS) enzymes are master regulators of mitophagy and mitobiogenesis, pharmaceutical modulators of UPS enzymes hold great promise as novel mitochondrial targeting therapies.
We believe that the secret to good health and aging is healthy mitochondria. Because mitochondrial distress underlies diverse tissue pathologies, targeted positive modulators can act as multi-indication therapies across neuromuscular, ischemic, and neurodegenerative conditions.
Translating mitochondrial quality control into targeted disease interventions.
Age-related loss of muscle mass and function (sarcopenia) is a deleterious hallmark of ageing. Impaired mitophagy and accumulation of damaged mitochondria contribute to the development of sarcopenia.
Activation of mitophagy and mitobiogenesis using compounds could attenuate sarcopenia and improve skeletal muscle health and performance.
Aging is characterized by a progressive decline in mitochondrial function. Age-associated accumulation of mitochondrial DNA mutations and mitochondrial proteotoxic stress contributes to mitochondrial dysfunction.
Mitochondrial damage contributes to inflammation that underlies aging. Restoring and maintaining mitochondrial homoeostasis can extend lifespan and improve organismal health.
Damage to mitochondria leads to loss of energy and depolarization, making dopaminergic brain regions highly vulnerable to Alzheimer’s and Parkinson’s disease.
At Myto Health we are working to validate small molecules that prevent heart attacks, promote rapid recovery from ischemia in animal models, and restore neuronal function.
Keeping in mind that aging and neurodegeneration go hand in hand and ubiquitin proteasome system is the guardian of cellular health. Maintaining good mitochondrial health is key to good health.
To address these poly-indication maladies we have screened small molecule libraries against ubiquitin ligases that promote mitophagy and mitobiogenesis to elevate these diseases.
Further medicinal chemistry of these molecules has improved potency and exposure on target tissues (brain). These molecules promote mitophagy and improve recovery from ischemic attack.
Myto Health has elucidated detailed mechanisms of action for small molecules, validating multi-indication properties across cellular and animal models to advance toward the clinic.
Connect with our scientific leadership in Malvern, PA to discuss collaborative licensing or trial integration.
